Home > Insider Trading > Filing (0000899243-19-020073)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1680581	Fulcrum Therapeutics Inc.	FULC	Pharmaceutical Preparations (2834)	I0

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1121404	Sanofi	54 Rue La Boetie Paris I0 75008		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock (Par Value $0.001)	Acquisiton	2019-07-22	464,285	$0.00	464,285	No	4	C	Indirect	Through its wholly-owned subsidiary, Aventis Inc.
Common Stock (Par Value $0.001)	Acquisiton	2019-07-22	93,750	$16.00	558,035	No	4	P	Indirect	Through its wholly-owned subsidiary, Aventis Inc.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	Through its wholly-owned subsidiary, Aventis Inc.
No	4	P	Indirect	Through its wholly-owned subsidiary, Aventis Inc.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock (par value $0.001)	Disposition	2019-07-22	3,250,000	$0.00	464,285	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

On July 22, 2019, the Series B Preferred Stock converted into the Issuer's Common Stock on a seven-for-one basis automatically upon the closing of the Issuer's initial public offering without payment or further consideration. The shares have no expiration date. As a result of the Issuer's initial public offering, the reporting person is no longer a 10% owner of FULC and is therefore no longer subject to Section 16 in connection with its transactions in the equity securities of FULC.
The reporting person acquired additional shares in the Issuer's initial public offering.